u/kian_ferreira

This. Step therapy is a paperwork requirement and it is beaten with documentation, not persuasion.

step therapy is a documentation problem, not an argument

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

ask for the clinical policy bulletin by number

deadlines run from the letter date, not from when you opened it

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.

the hepatic data is what makes this compound different from the others

This is the framing the board needs. It is a hepatic programme first.

The boring middle lasted the longest and it is the part I am most proud of.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

What are you actually celebrating today? Genuine question.

Stalled for 24 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

Yes. Clothes fitting differently arrives well before the scale acknowledges anything.

phase 2 in liver disease is a different evidence question from weight

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

Was there potency testing on the finished preparation, or only on the starting material?

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

prior authorisation criteria change every plan year

What exactly does the denial letter give as the reason?

if a clinic will not name the facility, that is your answer

Are you reading the publication or a summary?

Disagreeing with this bit: that number comes from a different programme with a different population.

compounded is not generic, there is no equivalence claim

Agreed that goal weights picked at the start are guesses. Mine was, and I revised it twice.

Switched between two compounded preparations and the concentration on the label was different.

vikram_mbeki is right about the concentration trap. It breaks arithmetic that has been reliable for months.

ask for the denial reason in writing, always

That criterion is from the previous plan year. The current bulletin has different wording.

ask for the denial reason in writing, always

What concentration is on the label, and does it match what you were expecting?

That is a waist measurement, not a weight, and the thread has been comparing them as though they were the same.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

comparison is the thief of everything on a board like this

the hepatic data is what makes this compound different from the others

Small correction, kindly meant: that is a range rather than a regain. Weight moves day to day in everybody.